Thus, it is plausible that blockade of LD-ATGL is a promising approach for targeting, not only cancer cells but also the heterogenic cancer stem cell population and for effective response to treatments in colon cancer patients. This evidence concerns the gene PNPLA2 and malignant colon neoplasm.